Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
230
-
Total 13F shares, excl. options
-
89.1M
-
Shares change
-
-1.59M
-
Total reported value, excl. options
-
$1.39B
-
Value change
-
-$23.1M
-
Put/Call ratio
-
0.6
-
Number of buys
-
118
-
Number of sells
-
-85
-
Price
-
$15.63
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q1 2024
284 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q1 2024.
NovoCure Ltd - Common Stock (NVCR) has 230 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.1M shares
of 112M outstanding shares and own 79.6% of the company stock.
Largest 10 shareholders include FMR LLC (16.1M shares), VANGUARD GROUP INC (10M shares), BlackRock Inc. (9.08M shares), Capital International Investors (8.86M shares), STATE STREET CORP (3.36M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.38M shares), Capital World Investors (2.31M shares), BAILLIE GIFFORD & CO (1.99M shares), MORGAN STANLEY (1.76M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.64M shares).
This table shows the top 230 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.